Introduction: Carcinoma of the stomach accounts for majority of deaths in the world. Targeted therapy with anti-HER2/neu therapies in in-vitro and in-vivo models of gastric carcinoma are under clinical trails as per the pre-clinical data. Materials & Methods: A prospective study was done from 2017 to 2020 for a period of 3 years from Narayana Medical College & Hospital, Nellore. Cases diagnosed as Gastric carcinoma during the study period were included and HER2/neu immunohistochemistry was done. Results: We received a total of 250 gastric biopsies, out of which 83 were gastric adenocarcinoma accounting for 33.2% with a peak incidence of 61 to 80 years old and male predominance. the most common type was Ulceroproliferative type, with tubular adenocarcinoma being the most common histologic type. As per the grading, moderately differentiated grade was predominant. HER2/neu over expression was noted in 16.95% of all the cases. Association was between HER2/neu over expression and grade of the tumour was significant. There was no association between HER2/neu expression and age of the person, morphological features, lymphovascular invasion or perineural invasion. Conclusion: HER2/neu expression in gastric carcinoma can be of great use in therapeutic modalities for gastric carcinoma.

Keywords: Carcinoma; Targeted; A prospective; received; HER2/neu.